464 related articles for article (PubMed ID: 27079871)
1. Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell.
Wang Z; Sun J; Feng Y; Tian X; Wang B; Zhou Y
Tumour Biol; 2016 Jul; 37(7):8515-28. PubMed ID: 27079871
[TBL] [Abstract][Full Text] [Related]
2. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Zhou W; Guo S; Liu M; Burow ME; Wang G
Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
[TBL] [Abstract][Full Text] [Related]
3. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential.
Wald O; Shapira OM; Izhar U
Theranostics; 2013; 3(1):26-33. PubMed ID: 23382783
[TBL] [Abstract][Full Text] [Related]
4. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
5. The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer.
Otsuka S; Bebb G
J Thorac Oncol; 2008 Dec; 3(12):1379-83. PubMed ID: 19057260
[TBL] [Abstract][Full Text] [Related]
6. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
7. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?
Hirbe AC; Morgan EA; Weilbaecher KN
Curr Pharm Des; 2010; 16(11):1284-90. PubMed ID: 20166978
[TBL] [Abstract][Full Text] [Related]
8. The good and bad faces of the CXCR4 chemokine receptor.
Teixidó J; Martínez-Moreno M; Díaz-Martínez M; Sevilla-Movilla S
Int J Biochem Cell Biol; 2018 Feb; 95():121-131. PubMed ID: 29288743
[TBL] [Abstract][Full Text] [Related]
9. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis.
Kucia M; Reca R; Miekus K; Wanzeck J; Wojakowski W; Janowska-Wieczorek A; Ratajczak J; Ratajczak MZ
Stem Cells; 2005 Aug; 23(7):879-94. PubMed ID: 15888687
[TBL] [Abstract][Full Text] [Related]
10. CXCL12 (SDF-1)/CXCR4 pathway in cancer.
Teicher BA; Fricker SP
Clin Cancer Res; 2010 Jun; 16(11):2927-31. PubMed ID: 20484021
[TBL] [Abstract][Full Text] [Related]
11. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
12. The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer.
Hartmann TN; Burger M; Burger JA
J Biol Regul Homeost Agents; 2004; 18(2):126-30. PubMed ID: 15471215
[TBL] [Abstract][Full Text] [Related]
13. The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis.
Gelmini S; Mangoni M; Serio M; Romagnani P; Lazzeri E
J Endocrinol Invest; 2008 Sep; 31(9):809-19. PubMed ID: 18997494
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin targets the stromal cell-derived factor-1-CXC chemokine receptor type 4 axis to suppress metastasis and invasion of ovarian cancer-initiating cells.
Yu ZH; Liu T; Zhao YH; Huang YY; Gao YT
Tumour Biol; 2014 May; 35(5):4637-44. PubMed ID: 24408020
[TBL] [Abstract][Full Text] [Related]
15. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases.
Phillips RJ; Burdick MD; Lutz M; Belperio JA; Keane MP; Strieter RM
Am J Respir Crit Care Med; 2003 Jun; 167(12):1676-86. PubMed ID: 12626353
[TBL] [Abstract][Full Text] [Related]
16. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?
Tavor S; Petit I
Semin Cancer Biol; 2010 Jun; 20(3):178-85. PubMed ID: 20637871
[TBL] [Abstract][Full Text] [Related]
17. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
Kijima T; Maulik G; Ma PC; Tibaldi EV; Turner RE; Rollins B; Sattler M; Johnson BE; Salgia R
Cancer Res; 2002 Nov; 62(21):6304-11. PubMed ID: 12414661
[TBL] [Abstract][Full Text] [Related]
18. Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis.
Wu R; Yu W; Yao C; Liang Z; Yoon Y; Xie Y; Shim H; Bai R
Eur J Med Chem; 2020 Jan; 185():111823. PubMed ID: 31698158
[TBL] [Abstract][Full Text] [Related]
19. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis.
Wang J; Loberg R; Taichman RS
Cancer Metastasis Rev; 2006 Dec; 25(4):573-87. PubMed ID: 17165132
[TBL] [Abstract][Full Text] [Related]
20. CXCR4 in breast cancer: oncogenic role and therapeutic targeting.
Xu C; Zhao H; Chen H; Yao Q
Drug Des Devel Ther; 2015; 9():4953-64. PubMed ID: 26356032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]